Literature DB >> 15117761

Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load.

Steven G Deeks1, Christina M R Kitchen, Lea Liu, Hua Guo, Ron Gascon, Amy B Narváez, Peter Hunt, Jeffrey N Martin, James O Kahn, Jay Levy, Michael S McGrath, Frederick M Hecht.   

Abstract

Although generalized T-cell activation is an important factor in chronic HIV disease pathogenesis, its role in primary infection remains poorly defined. To investigate the effect of immune activation on T-cell changes in subjects with early HIV infection, and to test the hypothesis that an immunologic activation "set point" is established early in the natural history of HIV disease, a prospective cohort of acutely infected adults was performed. The median density of CD38 molecules on CD4+ and CD8+ T cells was measured longitudinally in 68 antiretroviral-untreated individuals and 83 antiretroviral-treated individuals. At study entry, T-cell activation was positively associated with viremia, with CD8+ T-cell activation levels increasing exponentially at plasma HIV RNA levels more than 10,000 copies/mL. Among untreated patients, the level of CD8+ T-cell activation varied widely among individuals but often remained stable within a given individual. CD8+ T-cell activation and plasma HIV RNA levels over time were independently associated with the rate of CD4+ T-cell loss in untreated individuals. These data indicate that immunologic activation set point is established early in HIV infection, and that this set point determines the rate at which CD4+ T cells are lost over time.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15117761     DOI: 10.1182/blood-2003-09-3333

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  383 in total

1.  Dissociation of CD154 and cytokine expression patterns in CD38+ CD4+ memory T cells in chronic HIV-1 infection.

Authors:  Enrique Espinosa; Christopher E Ormsby; Gustavo Reyes-Terán; Robert Asaad; Scott F Sieg; Michael M Lederman
Journal:  J Acquir Immune Defic Syndr       Date:  2010-12       Impact factor: 3.731

2.  Rapid HIV Progression Is Associated with Extensive Ongoing Somatic Hypermutation.

Authors:  Ben S Wendel; Yajing Fu; Chenfeng He; Stefany M Hernandez; Mingjuan Qu; Zining Zhang; Yongjun Jiang; Xiaoxu Han; Junjie Xu; Haibo Ding; Ning Jiang; Hong Shang
Journal:  J Immunol       Date:  2020-06-26       Impact factor: 5.422

3.  HIV-1 infection abrogates CD8+ T cell mitogen-activated protein kinase signaling responses.

Authors:  Timothy Q Crawford; Lishomwa C Ndhlovu; Alice Tan; Alex Carvidi; Frederick M Hecht; Elizabeth Sinclair; Jason D Barbour
Journal:  J Virol       Date:  2011-09-21       Impact factor: 5.103

Review 4.  HIV and inflammation: mechanisms and consequences.

Authors:  Peter W Hunt
Journal:  Curr HIV/AIDS Rep       Date:  2012-06       Impact factor: 5.071

5.  Key Concepts in the Early Immunology of HIV-1 Infection.

Authors:  Basile Siewe; Alan Landay
Journal:  Curr Infect Dis Rep       Date:  2012-02       Impact factor: 3.725

Review 6.  The role of cytokines in the pathogenesis and treatment of HIV infection.

Authors:  Marta Catalfamo; Cecile Le Saout; H Clifford Lane
Journal:  Cytokine Growth Factor Rev       Date:  2012-06-26       Impact factor: 7.638

7.  Interleukin-7 receptor signaling is deficient in CD4+ T cells from HIV-infected persons and is inversely associated with aging.

Authors:  Douglas A Bazdar; Magdalena Kalinowska; Scott F Sieg
Journal:  J Infect Dis       Date:  2009-04-01       Impact factor: 5.226

8.  Delaying a treatment switch in antiretroviral-treated HIV type 1-infected patients with detectable drug-resistant viremia does not have a profound effect on immune parameters: AIDS Clinical Trials Group Study A5115.

Authors:  Allan R Tenorio; Hongyu Jiang; Yu Zheng; Barbara Bastow; Daniel R Kuritzkes; John A Bartlett; Steven G Deeks; Alan L Landay; Sharon A Riddler
Journal:  AIDS Res Hum Retroviruses       Date:  2009-02       Impact factor: 2.205

Review 9.  Nonhuman primate models of human viral infections.

Authors:  Jacob D Estes; Scott W Wong; Jason M Brenchley
Journal:  Nat Rev Immunol       Date:  2018-06       Impact factor: 53.106

10.  Reduced immune activation during tenofovir-emtricitabine therapy in HIV-negative individuals.

Authors:  Jose R Castillo-Mancilla; Amie Meditz; Cara Wilson; Jia-Hua Zheng; Brent E Palmer; Eric J Lee; Edward M Gardner; Sharon Seifert; Becky Kerr; Lane R Bushman; Samantha MaWhinney; Peter L Anderson
Journal:  J Acquir Immune Defic Syndr       Date:  2015-04-15       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.